Case Report. Strategie di intervento e gestione farmacologica di un paziente con disturbo da uso di alcol in comorbidità con aspetti depressivi ed insonnia

Elena Tamussi

doi:10.3280/mis68-2024oa19131

Newsletter "Clinica dell'Alcolismo"

N. 68 (2024)

Case Report. Strategie di intervento e gestione farmacologica di un paziente con disturbo da uso di alcol in comorbidità con aspetti depressivi ed insonnia

Elena Tamussi^▸^▾

SCARICA QUI IL PDF

DOI: https://doi.org/10.3280/mis68-2024oa19131
Inviata: 10 gennaio 2025
Pubblicato: 20-02-2025

Riferimenti bibliografici

American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). American Psychiatric Pub.
World Health Organization (2018). Global status report on alcohol and health 2018.
Addolorato G. et al. (2009). Role of GABAergic system in alcoholism and stress: focus on acamprosate and baclofen. Alcohol and Alcoholism, 44(2): 146-155.
Koob G.F., Volkow N.D. (2016). Neurobiology of addiction: a neurocircuitry analysis. The Lancet Psychiatry, 3(8): 760-773.
Möller H.J., Witkowski T. (2010). Sodium oxybate (gamma-hydroxybutyrate) in the treatment of alcohol dependence: a review of the clinical evidence. CNS Drugs, 24(11): 981-992.
Gessa G.L. et al. (2000). Gamma-hydroxybutyric acid (GHB) and alcoholism: overview of the pharmacological properties and therapeutic possibilities. Alcohol, 20(3): 257-265.
Gallimberti L. et al. (1992). Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome. The Lancet, 339(8794): 146-149.
Guy W. (1976). Clinical Global Impressions. In: Guy W. (ed)., ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, MD: National Institute of Mental Health, pp. 218-22.
Wing J.K., Beevor A.S., Curtis R.H., Park S.B., Hadden S., Burns A. (1998). Health of the Nation Outcome Scales (HoNOS): Research and development. Br J Psychiatry, 172(1): 11-18.
American Psychiatric Association (2001). DSM-IV-TR: Manuale diagnostico e statistico dei disturbi mentali. 4ª edizione, Text Revision. Milano: Masson.
Saunders J.B., Aasland O.G., Babor T.F., de la Fuente J.R., Grant M. (1993). Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction, 88(6): 791-804.
Bernstein D.P., Fink L., Handelsman L., Foote J., Lovejoy M., Wenzel K., Sapareto E., Ruggiero J. (1994). Initial reliability and validity of a new retrospective measure of child abuse and neglect. Am J Psychiatry, 151(8): 1132-1136.
Sullivan J.T., Sykora K., Schneiderman J., Naranjo C.A., Sellers E.M. (1989). Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar). Br J Addict., 84(11): 1353-1357.
Bastien C.H., Vallières A., Morin C.M. (2001). Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med., 2(4): 297-307.

Metriche

Caricamento metriche ...

Come citare

Tamussi, E. (2025). Case Report. Strategie di intervento e gestione farmacologica di un paziente con disturbo da uso di alcol in comorbidità con aspetti depressivi ed insonnia. Mission - Open Access, (68). https://doi.org/10.3280/mis68-2024oa19131

[1] American Psychiatric Association (2013). Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). American Psychiatric Pub.

[2] World Health Organization (2018). Global status report on alcohol and health 2018.

[3] Addolorato G. et al. (2009). Role of GABAergic system in alcoholism and stress: focus on acamprosate and baclofen. Alcohol and Alcoholism, 44(2): 146-155.

[4] Koob G.F., Volkow N.D. (2016). Neurobiology of addiction: a neurocircuitry analysis. The Lancet Psychiatry, 3(8): 760-773.

[5] Möller H.J., Witkowski T. (2010). Sodium oxybate (gamma-hydroxybutyrate) in the treatment of alcohol dependence: a review of the clinical evidence. CNS Drugs, 24(11): 981-992.

[6] Gessa G.L. et al. (2000). Gamma-hydroxybutyric acid (GHB) and alcoholism: overview of the pharmacological properties and therapeutic possibilities. Alcohol, 20(3): 257-265.

[7] Gallimberti L. et al. (1992). Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome. The Lancet, 339(8794): 146-149.

[8] Guy W. (1976). Clinical Global Impressions. In: Guy W. (ed)., ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, MD: National Institute of Mental Health, pp. 218-22.

[9] Wing J.K., Beevor A.S., Curtis R.H., Park S.B., Hadden S., Burns A. (1998). Health of the Nation Outcome Scales (HoNOS): Research and development. Br J Psychiatry, 172(1): 11-18.

[10] American Psychiatric Association (2001). DSM-IV-TR: Manuale diagnostico e statistico dei disturbi mentali. 4ª edizione, Text Revision. Milano: Masson.

[11] Saunders J.B., Aasland O.G., Babor T.F., de la Fuente J.R., Grant M. (1993). Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction, 88(6): 791-804.

[12] Bernstein D.P., Fink L., Handelsman L., Foote J., Lovejoy M., Wenzel K., Sapareto E., Ruggiero J. (1994). Initial reliability and validity of a new retrospective measure of child abuse and neglect. Am J Psychiatry, 151(8): 1132-1136.

[13] Sullivan J.T., Sykora K., Schneiderman J., Naranjo C.A., Sellers E.M. (1989). Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment for Alcohol scale (CIWA-Ar). Br J Addict., 84(11): 1353-1357.

[14] Bastien C.H., Vallières A., Morin C.M. (2001). Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Med., 2(4): 297-307.